Company intelligence / Profile preview
Biomind Labs
Canelones, Canelones Department, Uruguaybiomindlabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biomind Labs has reported positive initial results from its Phase II trial of BMND01 for treatment-resistant depression and unprecedented positive results from a Phase II trial of BMND08 for depression and anxiety in Alzheimer’s disease. The company also has several candidates at earlier clinical or preclinical stages targeting neurological and psychiatric conditions
- Therapeutic areas
- PsychiatryRheumatologyEndocrinologyImmunologyNeurology
- Modalities
- Small molecules (notably tryptamines and phenethylamines)Nanotech-based drug delivery systems
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Biomind Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomind Labs.